Literature DB >> 11421260

Synthesis and antiplatelet activity of some 2,7-di(N-cycloamino)-3-phenyl-1,8-naphthyridine derivatives.

P L Ferrarini1, M Badawneh, F Franconi, C Manera, M Miceli, C Mori, G Saccomanni.   

Abstract

Several 2,7-di(N-cycloamino)-3-phenyl-1,8-naphthyridine derivatives were synthesized and tested for their ability to inhibit human platelet aggregation in vitro induced by arachidonic acid, collagen and ADP. Only five compounds showed any appreciable activity, and the results of all the active derivatives were similar to those of papaverine in the test with arachidonic acid and collagen. Moreover, the most active compounds were investigated in the test with ADP and again showed a significant activity. The tested compounds that possessed the best activity were also shown to increase the c-AMP level significantly without involving the adenylyl cyclase system.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11421260     DOI: 10.1016/s0014-827x(01)01075-8

Source DB:  PubMed          Journal:  Farmaco        ISSN: 0014-827X


  3 in total

1.  An efficient Synthesis and Photophysical Properties of 1H-pyrazolo-[3,4-b]pyridine and pyrazolo[3,4-b][1,8]naphthyridines.

Authors:  Raviraj Deore; Kunal Dingore; Madhukar Jachak
Journal:  J Fluoresc       Date:  2015-09-28       Impact factor: 2.217

2.  Effects of anti-inflammatory [1, 2, 4]triazolo[4, 3-a] [1, 8]naphthyridine derivatives on human stimulated PMN and endothelial cells: an in vitro study.

Authors:  Chiara Dianzani; Massimo Collino; Margherita Gallicchio; Mario Di Braccio; Giorgio Roma; Roberto Fantozzi
Journal:  J Inflamm (Lond)       Date:  2006-03-28       Impact factor: 4.981

3.  General pathway for a convenient one-pot synthesis of trifluoromethyl-containing 2-amino-7-alkyl(aryl/heteroaryl)-1,8-naphthyridines and fused cycloalkane analogues.

Authors:  Helio G Bonacorso; Rosália Andrighetto; Nícolas Krüger; Nilo Zanatta; Marcos A P Martins
Journal:  Molecules       Date:  2011-03-30       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.